|
1.
|
|
11 p, 987.9 KB |
Participants' satisfaction with colorectal cancer screening programs : A systematic review
/
Selva, A. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Mosconi, Giansanto (University of Pavia) ;
Cacitti, Stefano (Health Protection Agency of Pavia) ;
Odone, Anna (University of Pavia) ;
Pylkkanen, Liisa (University of Turku) ;
Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ;
Torà, Núria (Althaia Xarxa Assistencial Universitària de Manresa) ;
Russo, Sara (University of Pavia) ;
Cadum, Ennio (Health Protection Agency of Pavia) ;
Deandrea, Silvia (Health Protection Agency of Pavia) ;
Universitat Autònoma de Barcelona
Since satisfaction with cancer screening experience can increase adherence to programs and contribute to reduce morbidity and mortality, its assessment is crucial for programs' effectiveness. Our aim was to conduct a systematic review about satisfaction of participants with organized colorectal cancer screening. [...]
2023 -  10.1016/j.ypmed.2023.107706
Preventive Medicine, Vol. 175 (october 2023) , p. 107706
|
|
|
2.
|
|
9 p, 412.0 KB |
Patient experience, satisfaction and shared decision-making in colorectal cancer screening : protocol of the mixed-methods study CyDESA
/
Selva, A (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
López López, Pilar (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Puig, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Macià, Francesc (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Selva Olid, Clara (UOC) ;
Álvarez-Pérez, Yolanda (Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC)) ;
Terraza, Rebeca (Generalitat de Catalunya. Departament de Salut) ;
Buron, Andrea (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Machlab, Salvador Tarek (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ;
Torà, Núria (Althaia Fundació de Manresa) ;
Rodríguez, Vanesa (Universitat Pompeu Fabra) ;
Barrufet, Cristina (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Aymar, Anna (Institut d'Investigació Biomèdica Sant Pau) ;
Baré i Mañas, Marisa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Universitat Autònoma de Barcelona
Colorectal cancer (CRC) screening programmes can reduce incidence and mortality from this condition if adherence to them is high. As patient experience and satisfaction are key factors in determining adherence to screening programmes, they need to be measured. [...]
2022 - 10.1136/bmjopen-2021-057687
BMJ open, Vol. 12 (may 2022)
|
|
|
3.
|
|
15 p, 3.2 MB |
p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis
/
Solé Font, Laura (Instituto de Salud Carlos III) ;
Lobo-Jarne, Teresa (Instituto de Salud Carlos III) ;
Álvarez-Villanueva, Daniel (Institut Català d'Oncologia) ;
Alonso-Marañón, Josune (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Guillén, Yolanda (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Guix, Marta (Universitat Pompeu Fabra) ;
Sangrador, Irene (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Rozalén, Catalina (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Vert, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Barbachano, Antonio (Universidad Autónoma de Madrid) ;
Lop Gros, Joan (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Salido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Bellosillo Paricio, Beatriz (Institut Hospital del Mar d'Investigacions Mèdiques) ;
García-Romero, Raquel (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Garrido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
González Miranda, Jessica (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Martínez-Iniesta, María (Institut Català d'Oncologia) ;
López-Arribillaga, Erika (Group of Biomedical Genomics) ;
Salazar, Ramón. (Institut Català d'Oncologia) ;
Torres, Ferran (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Iglesias, Mar (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Celià-Terrassa, Toni (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Munoz, Alberto (Instituto de Salud Carlos III) ;
Villanueva, Alberto (Institut Català d'Oncologia) ;
Bigas Salvans, Anna (Instituto de Salud Carlos III) ;
Espinosa, Lluís (Instituto de Salud Carlos III) ;
Universitat Autònoma de Barcelona
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. [...]
2022 - 10.1038/s41467-022-30382-9
Nature communications, Vol. 13 Núm. 1 (december 2022) , p. 2866
|
|
|
4.
|
|
17 p, 1.9 MB |
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial
/
Iveson, Timothy J. (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Kerr, Rachel S. (Department of Oncology, University of Oxford, Oxford, UK) ;
Saunders, Mark P. (The Christie Hospital, Manchester, UK) ;
Cassidy, Jim (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Hollander, Niels Henrik (Westmead Hospital) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Haydon, Andrew (Australasian Gastro-Intestinal Trials Group, Melbourne, VIC, Australia) ;
Glimelius, Bengt (IGP, University of Uppsala, Uppsala, Sweden) ;
Harkin, Andrea (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Allan, Karen (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
McQueen, John (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Scudder, Claire (OCTO, University of Oxford, Department of Oncology, Oxford, UK) ;
Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ;
Briggs, Andrew (Memorial Sloan-Kettering Cancer Centre) ;
Waterston, Ashita (Beatson West of Scotland Cancer Centre (Glasgow, Regne Unit)) ;
Medley, Louise (Royal United Hospital, Bath, UK) ;
Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Ellis, Richard (Royal Cornwall Hospital NHS Trust, Truro, UK) ;
Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK) ;
Dhadda, Amandeep S. (Castle Hill Hospital) ;
Harrison, Mark (Mount Vernon Cancer Centre, Northwood, UK) ;
Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ;
Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ;
Rees, Charlotte (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Olesen, Rene K. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Propper, David (Barts Cancer Institute (BCI)) ;
Bridgewater, John (UCL Cancer Institute, University College London, London UK) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK) ;
Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK) ;
Webb, Andrew (Brighton and Sussex University Hospital Trust) ;
Cunningham, David (Royal Marsden Hospital (Regne Unit)) ;
Hickish, Tamas (Poole Hospital, Bournemouth University, Bournemouth, UK) ;
Weaver, Andrew (Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford, UK) ;
Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ;
Wasan, Harpreet S.. (Hammersmith Hospital (Londres)) ;
Paul, James (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Universitat Autònoma de Barcelona
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. [...]
2018 - 10.1016/S1470-2045(18)30093-7
The Lancet. Oncology, Vol. 19 (april 2018) , p. 562-578
|
|
|
5.
|
|
15 p, 2.9 MB |
MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer
/
Mattesen, T. B. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Rasmussen, M. H. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Sandoval, J. (Instituto de Investigación Sanitaria La Fe) ;
Ongen, H. (Genetic Medicine and Development. University of Geneva Medical School-CMU) ;
Árnadóttir, S. S. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Gladov, J. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Castro de Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Madsen, A. H. (Department of Surgery. Hospitalsenheden Vest) ;
Laurberg, S. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Dermitzakis, Emmanouil T (University of Geneva Medical School) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Andersen, Claus Lindbjerg (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Bramsen, Jesper Bertram (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Universitat Autònoma de Barcelona
Transcriptional characterization and classification has potential to resolve the inter-tumor heterogeneity of colorectal cancer and improve patient management. Yet, robust transcriptional profiling is difficult using formalin-fixed, paraffin-embedded (FFPE) samples, which complicates testing in clinical and archival material. [...]
2020 - 10.1038/s41467-020-16000-6
Nature communications, Vol. 11 Núm. 1 (january 2020) , p. 2025
|
|
|
6.
|
|
32 p, 1.2 MB |
Release of targeted protein nanoparticles from functional bacterial amyloids : A death star-like approach
/
Unzueta Elorza, Ugutz (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Céspedes, María Virtudes (Institut d'Investigació Biomèdica Sant Pau) ;
Sala, Rita (Institut d'Investigació Biomèdica Sant Pau) ;
Álamo, Patricia (Institut d'Investigació Biomèdica Sant Pau) ;
Sánchez Chardi, Alejandro (Universitat Autònoma de Barcelona. Servei de Microscòpia) ;
Pesarrodona Roches, Mireia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Sánchez-García, Laura (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Cano-Garrido, Olivia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Mangues, Ramon 1957- (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Seras-Franzoso, Joaquin (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Sustained release of drug delivery systems (DDS) has the capacity to increase cancer treatment efficiency in terms of drug dosage reduction and subsequent decrease of deleterious side effects. In this regard, many biomaterials are being investigated but none offers morphometric and functional plasticity and versatility comparable to protein-based nanoparticles (pNPs). [...]
2018 - 10.1016/j.jconrel.2018.04.004
Journal of Controlled Release, Vol. 279 (June 2018) , p. 29-39
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
